Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid

See also
Status	Clinical Trial	Phase
Completed	`NCT04509804` - Target Gene Sequencing for Advanced Stage, Relapsed or Refractory Natural Killer/T-cell Lymphoma
Recruiting	`NCT06250595` - European Rare Blood Disorders Platform (ENROL)
Completed	`NCT01110824` - Prevention of Left Ventricular Dysfunction During Chemotherapy	Phase 3

See also

Status

Clinical Trial

Phase

Completed

NCT04509804 - Target Gene Sequencing for Advanced Stage, Relapsed or Refractory Natural Killer/T-cell Lymphoma

Recruiting

NCT06250595 - European Rare Blood Disorders Platform (ENROL)

Completed

NCT01110824 - Prevention of Left Ventricular Dysfunction During Chemotherapy

Phase 3

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04897139
Study type	Interventional
Source	Shanghai Jiao Tong University School of Medicine
Contact	Jiong Hu
Phone	86-21-64370045
Email	hj10709@rjh.com.cn
Status	Recruiting
Phase	Phase 2
Start date	January 1, 2021
Completion date	December 1, 2024

Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms